Australia's peak science agency has entered a landmark five-year partnership with one of the world's leading vaccine makers to strengthen the nation's defences against emerging biosecurity threats. CSIRO and Moderna have signed an agreement to establish a biosecurity accelerator program, centred on infectious disease research and the mRNA vaccine technology that underpinned the global response to COVID-19.
What the CSIRO–Moderna Biosecurity Partnership Involves
The program will bring together Australian scientists and Moderna's expertise in mRNA technology — a platform that works by delivering genetic instructions to the immune system, enabling it to recognise and fight disease. This differs from conventional vaccines, which rely on physical components of a virus or bacterium to trigger an immune response.
Moderna deployed this technology to develop its COVID-19 vaccine and is currently running clinical trials for a bird flu vaccine. As part of the new partnership, biosecurity safeguards in the agricultural sector will also be examined and rolled out across Australia and the broader Pacific region.
Government Ministers Back the Initiative
Defence Minister Richard Marles highlighted the national security dimension of the collaboration, saying Australia's capacity to respond swiftly to biosecurity threats was a cornerstone of the country's resilience.
"Initiatives like this help ensure Australia is better equipped to meet emerging challenges while contributing to security, stability and prosperity across our region," Marles said.
Science Minister Tim Ayres said the partnership would deliver direct benefits to researchers at CSIRO, giving them the opportunity to learn from a company that has pushed the boundaries of modern biotechnology.
"Some of the nation's leading researchers will have the chance to learn from Moderna, who have pushed the boundaries of biotechnology forward," Ayres said.
mRNA Technology and Australia's Pandemic Preparedness
The focus on mRNA is significant given the technology's demonstrated speed and adaptability during the responses to the COVID-19 pandemic, when vaccine developers were able to move from pathogen identification to clinical trials in record time. By embedding this expertise within CSIRO, the program aims to give Australia a faster development pathway for future infectious disease responses.
The partnership also has a regional dimension, with agricultural biosecurity measures intended to be assessed and applied across the Pacific — reflecting growing concern about the cross-border nature of disease threats to both human and animal health.
What Comes Next
With the five-year agreement now in place, CSIRO researchers are expected to work alongside Moderna specialists as part of the accelerator structure. The program's dual focus — on human infectious diseases and agricultural biosecurity — positions it as a broad-based effort to future-proof Australia against threats that could emerge rapidly and without warning.
For the latest on Australia's international commitments and scientific investments, see our report on how cutting-edge research is reshaping medicine and metabolic health.
